Intra-arterial administration of TNF-α followed by arterial ablation is an effective therapy for a regionally confined TNF-resistant rat mammary adenocarcinoma

Cancer Immunology, Immunotherapy

Volumn 52, Issue 1, 2003, Pages 10-16

  Badgwell, Brian D ^a   Valentino, Daniel J ^a   Jeffes, Edward W B ^b   Dieffenbach, Kevin ^c   Dulkanchainun, Sathit B ^d   Yamamoto, Robert S ^d   Granger, Gale A ^d   Jakowatz, James G ^c   Carson, William E ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Intra arterial; Tumor necrosis factor

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ARTIFICIAL EMBOLISM; BREAST ADENOCARCINOMA; CANCER INHIBITION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; LIVER METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR VOLUME;

EID: 0037264751     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-002-0330-2     Document Type: Article

References (37)

1. Old LJ (1985) Tumor necrosis factor (TNF). Science 230:630
2. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72:3666
3. Asher A, Mule JJ, Reichert CM, Shiloni E, Rosenberg SA (1987) Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 138:963
4. Haranaka K, Satomi N, Sakurai A (1984) Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer 34:263
5. Creasey AA, Reynolds MT, Laird W (1986) Cures and partial regression of murine and human tumors by recombinant tumor necrosis factor. Cancer Res 46:5687
6. Mule JJ, Asher A, McIntosh J, Lafreniere R, Shiloni E, Lefor A, Reichert CM, Rosenberg SA (1987) Antitumor effect of recombinant tumor necrosis factor-alpha against murine sarcomas at visceral sites: tumor size influences the response to therapy. Cancer Immunol Immunother 26:202
7. Beutler B, Milsark IW, Cerami AC (1985) Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869
8. Chapman PB, Lester TJ, Casper ES, Gabrilove JL, Wong GY, Kempin SJ, Gold PJ, Welt S, Warren RS, Starnes HF, Sherwin SA, Old LJ, Oettgen HF (1987) Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol 5:1942
9. Blick M, Sherwin SA, Rosenblum M, Gutterman J (1987) Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 47:2986
10. Bollon AP, Berent SL, Torczynski RM, Hill NO, Lemesheu Y, Hill JM, Jia FL, Joher A, Pichyangkul S, Khan A (1988) Human cytokines, tumor necrosis factor, and interferons: gene cloning, animal studies, and clinical trials. J Cell Biochem 36:353
11. Moritz T, Niederle N, Baumann J, May D, Kurschel E, Osieka R, Kempeni J, Schlick E. Schmidt CG (1989) Phase I study of recombinant human tumor necrosis factor-alpha in advanced malignant disease. Cancer Immunol Immunother 29:144
12. Kimura K, Taguchi T, Urushizaki I, Ohno R, Abe O, Furue H, Hattori T, Ichihashi H, Inoguchi K, Majima H, Niitani H, Ota K, Saito T, Suga S, Suzuoki Y, Wakui A, Yamada K (1987) Phase I study of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 20:223
13. Steinmetz T, Schaadt M, Gahl R, Schenk V, Deihl V, Pfreundschuh M (1988) Phase I study of 24-hour continuous intravenous infusion of recombinant human tumor necrosis factor. J Biol Response Modif 7:417
14. Bartsch HH, Pfizenmaier K, Schroeder M, Nagel GA (1989) Intralesional application of recombinant human tumor necrosis factor-alpha induces local tumor regression in patients with advances malignancies. Eur J Cancer Clin Oncol 25:287
15. Martijn HH, Oldhoff J, Koops HS (1982) Hyperthermic regional perfusion with melphalan and a combination of melphalan and actinomycin D in the treatment of locally metastasized malignant melanomas of the extremities. J Surg Oncol 20:9
16. Bland KI, Kimura AK, Brenner DE, Basinger MA, Hirsch M, Hawkins IF Jr, Pierson KK, Copeland EM III (1989) A phase II study of the efficacy of diamminedichloroplatinum (cisplatin) for the control of locally recurrent and intransit malignant melanoma of the extremities using tourniquet outflow-occlusion techniques. Ann Surg 209:73
17. Niederhuber JE, Ensminger W, Gyves J, Thrall J, Walker S, Cozzi E (1984) Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer 53:1336
18. Calvo DB III, Patt YZ, Wallace S, Chuang VP, Benjamin RS, Pritchard JD, Hersh EM, Bodey GP Sr, Mavligit GM (1980) Phase I-II trial of percutaneous intra-arterial cis-diamine dichloroplatinum (II) for regionally confined malignancy. Cancer 45:1278
19. Patel NH, Jindal RM (2001) The role of chemoembolization in the treatment of colorectal hepatic metastases. Hepatogastroenterology 48:448
20. Jakowatz JG, Ginn GE, Snyder LM, Dieffenbach KW, Wile AG (1991) Increased cisplatin tissue levels with prolonged arterial infusion in the rat. Cancer 67:2828
21. Hilf R, Michel I, Bell C, Freeman J, Borman A (1965) Biochemical and morphologic properties of a new lactating mammary tumor line in the rat. Cancer Res 25:286
22. Gatanaga T, Hwang CD, Kohr W, Cappuccini F, Lucci JA III, Jeffes EW, Lentz R, Tomich J, Yamamoto RS, Granger GA (1990) Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. Proc Natl Acad Sci USA 87:8781
23. Dunn OJ (1961) Multiple comparisons among means. J Am Stat Assoc 56:52
24. Eggermont AM, Koops HS, Klausner JM, Kroon BB, Schlag PM, Lienard D, van Geel AN, Hoekstra HJ, Meller I, Nieweg OE, Kettelhack C, Ben-Ari G, Pector JC, Lejeune FJ (1996) Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 224:756
25. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon-gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10:52
26. Lienard D, Eggermont AM, Koops HS, Kroon BB, Rosenkaimer F, Autier P, Lejeune FJ (1994) Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res 4:21
27. Bartlett DL, Ma G, Alexander HR, Libutti SK, Fraker DL (1997) Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer 80:2084
28. Eggermont A, Koops HS, Klausner JM, Lienard D, Kroon BB, Schlag PM, Ben-Ari G, Lejeune FJ (1997) Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas. Semin Oncol 24:547
29. Eggermont AM, Koops HS, Lienard D, Kroon BB, van Geel AN, Hoekstra HJ, Lejeune FJ (1996) Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 14:2653
30. Lejeune FJ, Ruegg C, Lienard D (1998) Clinical applications of TNF-alpha in cancer. Curr Opin Immunol 10:573
31. Alexander HR Jr, Bartlett DL, Libutti SK (2000) Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to the liver. Oncologist 5:416
32. Hafstrom L, Naredi P (1998) Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia TNF-alpha and melphalan: Swedish experience. Recent Results Cancer Res 147:120
33. de Vries MR, Rinkes IH, van de Velde CJ, Wiggers T, Tollenaar RA, Kuppen PJ, Vahrmeijer AL, Eggermont AM (1998) Isolated hepatic perfusion with tumor necrosis factor-alpha and melphalan: experimental studies in pigs and phase I data from humans. Recent Results Cancer Res 147:107
34. Alexander H, Bartlett D, Libutti S (1998) Isolated hepatic perfusion: a potentially effective treatment for patients with metastatic or primary cancers confined to the liver. Cancer J Sci Am 4:2
35. Alexander HR Jr, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA (1998) Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 16:1479
36. Naomoto Y, Sadamori H, Matsukawa H, Shirakawa Y, Yamatsuji T, Saito S, Hino N, Isozaki H, Takakura N, Tanaka N (1999) Multiple liver metastases of breast cancer: report of a case successfully treated with hormone-cytokine-chemotherapy. Jpn J Clin Oncol 29:390
37. Tellez C, Benson AB III, Lyster MT, Talamonti M, Shaw J, Braun MA, Nemcek AA Jr, Vogelzang RL (1998) Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer 82:1250